Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPRT1 | P00492 | 16/20 | 0.49 |
| ▸ | PNP | P00491 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Leteprinim SCHEMBL358491 | 0.99 | HPRT1 (0.50) | HPRT1PNPLMNA | |
| Leteprinim SCHEMBL6931317 | 0.98 | HPRT1 (0.49) | HPRT1PNP | |
| Leteprinim SCHEMBL6935182 | 0.98 | HPRT1 (0.49) | HPRT1PNPLMNA | |
| Leteprinim SCHEMBL194354 | 0.88 | HPRT1 (0.48) | HPRT1PNPLMNA | |
| SCHEMBL1247298 | 0.85 | GAA (0.54) | HPRT1 | |
| SCHEMBL5258348 | 0.83 | TK1 (0.54) | HPRT1PNP | |
| Leteprinim SCHEMBL358492 | 0.82 | HSD17B10 (0.42) | LMNA | |
| SCHEMBL7684224 | 0.81 | HPRT1 (0.49) | HPRT1PNP | |
| Hydrochloric Acid SCHEMBL7438455 | 0.80 | HDAC3 (0.52) | HPRT1LMNA | |
| SCHEMBL7397072 | 0.78 | HPRT1 (0.59) | HPRT1PNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1684784-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A NEUROTROPHIC FACTOR-MODULATING AGENT FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM MEDIATED DISORDERS | Pharmacia & Upjohn Company LLC (US) | 2006-08-02 | — | — | EP | claimed |
| EP-1628532-A2 | METHODS FOR THE PROTECTION OF MEMORY AND COGNITION | Microbia, Inc. (US) | 2006-03-01 | — | — | EP | claimed |
| US-20050148589-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a neurotrophic factor-modulating agent for the treatment of central nervous system mediated disorders | PHARMACIA & UPJOHN COMPANY LLC (US) | 2005-07-07 | — | — | US | claimed |
| WO-2005046615-A2 | COMPOSITIONS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM MEDIATED DISORDERS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2005-05-26 | — | — | WO | claimed |
| US-20050020945-A1 | Acoustically-aided cerebrospinal-fluid manipulation for neurodegenerative disease therapy | TOSAYA CAROL A (US) | 2005-01-27 | — | — | US | claimed |
| US-20050004104-A1 | Methods for the protection of memory and cognition | IRONWOOD PHARMACEUTICALS, INC. | 2005-01-06 | — | — | US | claimed |
| WO-2004108085-A2 | METHODS FOR THE PROTECTION OF MEMORY AND COGNITION | MICROBIA, INC. (US) | 2004-12-16 | — | — | WO | claimed |
| US-20040049134-A1 | System and methods for treatment of alzheimer's and other deposition-related disorders of the brain | TOSAYA CAROL A (US) | 2004-03-11 | — | — | US | claimed |
| EP-3157408-B1 | DEVICES TO PROVIDE HANDS FREE SCLERAL DEPRESSION DURING OPHTHALMIC PROCEDURES | ALCON INC (CH) | 2026-03-25 | — | — | EP | disclosed |
| EP-4714407-A2 | DEVICES TO PROVIDE HANDS FREE SCLERAL DEPRESSION DURING OPHTHALMIC PROCEDURES | Alcon Inc. (CH) | 2026-03-25 | — | — | EP | disclosed |
| US-20250057694-A1 | DEVICES AND METHODS TO PROVIDE HANDS FREE SCLERAL DEPRESSION AND ILLUMINATION DURING OPHTHALMIC PROCEDURES | Ganihand, LLC (US) | 2025-02-20 | — | — | US | disclosed |
| US-11266395-B2 | Devices and methods to provide hands free scleral depression during ophthalmic procedures | Ganihand, LLC (US) | 2022-03-08 | — | — | US | disclosed |
| CN-110290781-A | The dosage form of stomach and intestine privileged site control release | 南京三迭纪医药科技有限公司 | 2019-09-27 | — | — | CN | disclosed |
| CN-107847398-B | Control the pharmaceutical dosage form of release | 南京三迭纪医药科技有限公司 | 2019-05-07 | — | — | CN | disclosed |
| US-20020040031-A1 | Methods for prevention of accumulation of amyloid beta peptide in the central nervous system | NEO THERAPEUTICS, INC. | 2002-04-04 | — | — | US | disclosed |
| WO-2002004449-A2 | METHODS FOR TREATMENT OF CONDITIONS AFFECTED BY ACTIVITY OF MULTIDRUG TRANSPORTERS | NEOTHERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | disclosed |
| WO-2002004450-A2 | METHODS FOR PREVENTION OF ACCUMULATION OF AMYLOID BETA PEPTIDE IN THE CENTRAL NERVOUS SYSTEM | NEOTHERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | disclosed |
| WO-2002004451-A2 | METHODS FOR STIMULATION OF SYNTHESIS OF SYNAPTOPHYSIN IN THE CENTRAL NERVOUS SYSTEM | NEOTHERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | disclosed |
| WO-2002004452-A2 | METHODS FOR TREATMENT OF DISEASE-INDUCED PERIPHERAL NEUROPATHY AND RELATED CONDITIONS | NEOTHERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | disclosed |
| WO-2002004448-A2 | METHODS FOR TREATMENT OF DRUG-INDUCED PERIPHERAL NEUROPATHY AND RELATED CONDITIONS | NEOTHERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004104-A1 | Methods for the protection of memory and cognition | PTGES2, PTGS2, PTGS1 | HPRT1 983/4885PNP 3281/4885LMNA 3639/4885 |
| US-20050148589-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a neurotrophic factor-modulating agent for the treatment of central nervous system mediated disorders | BDNF, NTRK2, NGF | HPRT1 3707/4885PNP 2597/4885LMNA 3783/4885 |
| US-20020040031-A1 | Methods for prevention of accumulation of amyloid beta peptide in the central nervous system | APP, BACE1, SARNP | HPRT1 10/4885PNP 9/4885LMNA 623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.